GMPPB
Basic information
Region (hg38): 3:49716844-49723973
Links
Phenotypes
GenCC
Source:
- muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14 (Definitive), mode of inheritance: AR
- congenital myasthenic syndrome (Strong), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy type 2T (Strong), mode of inheritance: AR
- muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14 (Strong), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy type 2T (Moderate), mode of inheritance: AR
- muscle-eye-brain disease (Supportive), mode of inheritance: AR
- congenital myasthenic syndromes with glycosylation defect (Supportive), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy type 2T (Supportive), mode of inheritance: AR
- congenital muscular dystrophy with cerebellar involvement (Supportive), mode of inheritance: AR
- congenital muscular dystrophy with intellectual disability (Supportive), mode of inheritance: AR
- autosomal recessive limb-girdle muscular dystrophy type 2T (Strong), mode of inheritance: AR
- muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14 (Strong), mode of inheritance: AR
- myopathy caused by variation in GMPPB (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14; Limb-girdle muscular dystrophy-dystroglycanopathy, type B, 14; Limb-girdle muscular dystrophy-dystroglycanopathy, type C, 14 | AR | Cardiovascular | Cardiovascular complications, including long QT syndrome and cardiomyopathy, have been described, and awareness may allow surveillance and prompt management | Audiologic/Otolaryngologic; Cardiovascular; Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic | 23768512 |
ClinVar
This is a list of variants' phenotypes submitted to
- Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14;Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14;Autosomal recessive limb-girdle muscular dystrophy type 2T (13 variants)
- not provided (5 variants)
- Autosomal recessive limb-girdle muscular dystrophy type 2T (3 variants)
- Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14;Autosomal recessive limb-girdle muscular dystrophy type 2T;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14 (3 variants)
- Autosomal recessive limb-girdle muscular dystrophy type 2T;Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14 (2 variants)
- Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14 (1 variants)
- Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14 (1 variants)
- Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14;Autosomal recessive limb-girdle muscular dystrophy type 2T (1 variants)
- Muscular dystrophy (1 variants)
- Elevated circulating creatine kinase concentration (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the GMPPB gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 73 | 76 | ||||
missense | 13 | 131 | 150 | |||
nonsense | 7 | |||||
start loss | 0 | |||||
frameshift | 15 | |||||
inframe indel | 6 | |||||
splice donor/acceptor (+/-2bp) | 8 | |||||
splice region | 10 | 12 | 22 | |||
non coding | 17 | 46 | 67 | |||
Total | 22 | 24 | 158 | 119 | 6 |
Highest pathogenic variant AF is 0.0000657
Variants in GMPPB
This is a list of pathogenic ClinVar variants found in the GMPPB region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-49717989-C-A | not specified | Uncertain significance (Nov 22, 2022) | ||
3-49718001-C-T | not specified | Uncertain significance (Apr 25, 2022) | ||
3-49718006-T-C | not specified | Uncertain significance (Mar 21, 2022) | ||
3-49718103-C-G | not specified | Uncertain significance (Oct 10, 2023) | ||
3-49718106-C-G | not specified | Uncertain significance (Aug 02, 2022) | ||
3-49718110-C-G | not specified | Uncertain significance (Jan 26, 2022) | ||
3-49718209-C-CCAGCGGCGG | Benign (Jul 01, 2022) | |||
3-49718213-C-T | not specified | Uncertain significance (Jan 20, 2023) | ||
3-49718232-G-C | not specified | Uncertain significance (Jul 15, 2021) | ||
3-49718244-G-C | not specified | Uncertain significance (Jun 29, 2023) | ||
3-49718307-T-C | not specified | Uncertain significance (May 31, 2023) | ||
3-49718412-A-C | not specified | Uncertain significance (May 16, 2024) | ||
3-49718425-C-T | Likely benign (Aug 01, 2022) | |||
3-49718427-C-T | not specified | Uncertain significance (Nov 08, 2022) | ||
3-49718510-A-C | not specified | Uncertain significance (Jun 14, 2023) | ||
3-49718514-G-C | not specified | Uncertain significance (May 01, 2022) | ||
3-49718515-C-A | not specified | Uncertain significance (Feb 26, 2024) | ||
3-49718544-G-T | not specified | Uncertain significance (Jan 18, 2022) | ||
3-49718579-A-G | not specified | Uncertain significance (Apr 15, 2024) | ||
3-49718622-C-G | not specified | Uncertain significance (Dec 05, 2022) | ||
3-49718653-C-G | not specified | Uncertain significance (Oct 27, 2022) | ||
3-49718670-G-A | not specified | Uncertain significance (May 23, 2023) | ||
3-49718696-G-A | not specified | Uncertain significance (May 15, 2023) | ||
3-49718727-G-T | not specified | Uncertain significance (May 20, 2024) | ||
3-49718736-C-A | not specified | Uncertain significance (Jun 02, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
GMPPB | protein_coding | protein_coding | ENST00000308375 | 8 | 7108 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
8.44e-7 | 0.759 | 125714 | 0 | 30 | 125744 | 0.000119 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.02 | 205 | 250 | 0.819 | 0.0000152 | 2498 |
Missense in Polyphen | 68 | 98.036 | 0.69362 | 1008 | ||
Synonymous | -0.454 | 108 | 102 | 1.06 | 0.00000605 | 800 |
Loss of Function | 1.28 | 12 | 17.8 | 0.674 | 8.10e-7 | 193 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000478 | 0.000478 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000793 | 0.0000703 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.000294 | 0.000294 |
Other | 0.000164 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the formation of GDP-mannose, an essential precursor of glycan moieties of glycoproteins and glycolipids. {ECO:0000250|UniProtKB:P0C5I2}.;
- Disease
- DISEASE: Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A14 (MDDGA14) [MIM:615350]: An autosomal recessive disorder characterized by congenital muscular dystrophy associated with brain anomalies, eye malformations, and profound mental retardation. The disorder includes a severe form designated as Walker-Warburg syndrome and a less severe phenotype known as muscle-eye-brain disease. MDDGA14 features include increased muscle tone, microcephaly, cleft palate, feeding difficulties, severe muscle weakness, sensorineural hearing loss, cerebellar hypoplasia, ataxia, and retinal dysfunction. {ECO:0000269|PubMed:23768512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Muscular dystrophy-dystroglycanopathy congenital with mental retardation B14 (MDDGB14) [MIM:615351]: A congenital muscular dystrophy characterized by severe muscle weakness apparent in infancy and mental retardation. Some patients may have additional features, such as microcephaly, cardiac dysfunction, seizures, or cerebellar hypoplasia. {ECO:0000269|PubMed:23768512}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Muscular dystrophy-dystroglycanopathy limb-girdle C14 (MDDGC14) [MIM:615352]: An autosomal recessive form of muscular dystrophy characterized by mild proximal muscle weakness with onset in early childhood. Some patients may have additional features, such as mild intellectual disability or seizures. {ECO:0000269|PubMed:23768512, ECO:0000269|PubMed:26310427, ECO:0000269|PubMed:28433477, ECO:0000269|PubMed:28478914}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Fructose and mannose metabolism - Homo sapiens (human);Amino sugar and nucleotide sugar metabolism - Homo sapiens (human);Fructose intolerance, hereditary;Fructose and Mannose Degradation;Fructosuria;Fructose Mannose metabolism;Post-translational protein modification;Metabolism of proteins;Synthesis of GDP-mannose;Synthesis of substrates in N-glycan biosythesis;Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein;Asparagine N-linked glycosylation;GDP-mannose biosynthesis
(Consensus)
Recessive Scores
- pRec
- 0.196
Intolerance Scores
- loftool
- rvis_EVS
- -0.34
- rvis_percentile_EVS
- 30.56
Haploinsufficiency Scores
- pHI
- 0.825
- hipred
- Y
- hipred_score
- 0.550
- ghis
- 0.423
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.976
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Gmppb
- Phenotype
Zebrafish Information Network
- Gene name
- gmppb
- Affected structure
- skeletal muscle cell
- Phenotype tag
- abnormal
- Phenotype quality
- sparse
Gene ontology
- Biological process
- GDP-mannose biosynthetic process
- Cellular component
- cytoplasm
- Molecular function
- mannose-1-phosphate guanylyltransferase activity;protein binding;GTP binding